• Daewoong Pharma’s third-quarter 2026 standalone operating profit rose 43.5% year over year to KRW 76.83 billion.
• Revenue increased 17.1% from a year earlier to KRW 415.84 billion.
• Net profit climbed 9.9% year over year to KRW 47.34 billion.
• Sequentially, operating profit fell 0.4%; net profit dropped 31.8%.
• For the first nine months of 2026, operating profit increased 14.8% to KRW 181.38 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daewoong Pharma published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261104800041), on November 04, 2026, and is solely responsible for the information contained therein.